Preview
Regardless of the many considerations, GR43175 has been shown to be effective when administered subcutaneously and orally as well as when administered intravenously in the treatment of acute migraine. It is now in phase III clinical trials and promises to provide a major breakthrough in migraine therapy. Importantly, further studies on its clinical mechanism of action are in progress and they will, it is hoped, be invaluable in elucidating the pathogenesis of migraine and vascular headache.
Keywords: vascular aetiology; acute migraine; treatment of migraine; clinical trials; vascular headache; pathogenesis
Chapter. 10736 words. Illustrated.
Subjects: Neuroscience
Go to Oxford Scholarship Online » abstract
Full text: subscription required
How to subscribe Recommend to my Librarian
Buy this work at Oxford University Press »
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.
